Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Annals of the Rheumatic Diseases|February 1, 2014
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialChristopher Ritchlin, Proton Rahman, Arthur Kavanaugh, et al.
Rheumatology (Oxford, England)|September 14, 2022
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysisPhilip J Mease, Iain B McInnes, Lai-Shan Tam, et al.
Nature Reviews. Rheumatology|February 16, 2021
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus studyLourdes M Perez-Chada, Rebecca H Haberman, Vinod Chandran, et al.
Rheumatology (Oxford, England)|December 5, 2021
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritisPeter Nash, Pascal Richette, Laure Gossec, et al.
The Journal of Rheumatology|August 1, 2024
Breakout Session and Report Back: Collaboration of Rheumatologists and Dermatologists for the Care of Patients With Psoriatic DiseaseDaniela Kampel Stolnicki, Laura C Coates, Charlotte E Gollins, et al.
Rheumatology (Oxford, England)|April 12, 2021
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysisPhilip J Mease, Iain B McInnes, Lai-Shan Tam, et al.
Arthritis and Rheumatism|December 4, 2010
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialPhilip Mease, Mark C Genovese, Geoffrey Gladstein, et al.
Rheumatology and Therapy|March 30, 2022
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)Georg Schett, Matthew J Loza, Arumugam Palanichamy, et al.
Lancet (London, England)|May 11, 2020
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trialIain B McInnes, Frank Behrens, Philip J Mease, et al.
Journal of Psoriasis and Psoriatic Arthritis|September 20, 2024
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting ProceedingsCarly Grant, Lourdes Perez-Chada, Rebecca H Haberman, et al.
Pageof 7